• Title, Summary, Keyword: Korean Pharmaceutical Company

Search Result 115, Processing Time 0.037 seconds

The effect of G009 on lipidperoxidation in rat liver microsome

  • Lee, June-Woo;Jeong, Hoon;Han, Man-Deuk;Kim, Su-Ung;Lee, Seung-Yong;Kim, Kee-Nam;Chung, Sung-Kyun;Baek, Seong-Jin;Song, Jae-Jin;Kim, Yong-Seok;Kang, Sang-Mo
    • Proceedings of the Korean Society of Applied Pharmacology
    • /
    • /
    • pp.107-107
    • /
    • 1995
  • The purpose of this study was to observe the effects of the polysaccharide(G009) obtained from liquid cultured Ganoderma lucidum IY009 on the lipidperoxidation in rat liver microsome. It is well known that the polysaccharide of G. lucidum have the hepatoprotective activity, antitumor activity etc., which was thought to have the relationship to anti-lipidperoxidation. In order to the estimate the effects of anti-lipidperoxidation of the polysaccharide obtained from G. lucidum IY009, enzymatic and nonenzymatic reaction were performed, in vitro, in rat liver microsome. In enzymatic lipid peroxidation reaction by ADP/FeCl$_3$/NADPH and $CCl_4$/NADPH, G009(1mg/ml) inhibited 77.4%, 39.4%, respectively, and the nonenzymatic reaction strongly exhibited 97.4% inhibition. And also, in enzymatic and nonenzymatic inducers treated with G009, the formation of MDA was progressively greater decreased by raising G009 concentration. These results suggest that anti-lipidperoxidation by G009 treatment may be play an important part in liver protection action.

  • PDF

Synthesis and Biological Properties of New 5-Cyano-1,1-disubstituted Phthalans for the Treatment of Premature Ejaculation

  • Kim, Dong-Sung;Kang, Kyung-Koo;Lee, Kyung-Seok;Ahn, Byoung-Ok;Yoo, Moo-Hi;Yoon, Seung-Soo
    • Bulletin of the Korean Chemical Society
    • /
    • v.29 no.10
    • /
    • pp.1946-1950
    • /
    • 2008
  • The synthesis of new 5-cyano-1,1-disubstituted phthalans having aromatic and aminoalkyl groups at C-1 position of phthalan ring and their biological evaluation are described. Most compounds exhibited comparable ejaculation-retarding effects to citalopram. Of these compounds, 3a, e showed excellent efficacy in delaying ejaculation.

Pharmacokinetic studies on ADME of G009

  • Deuk, Han-Man;Hoon Jeong;Lee, June-Woo;Kim, Su-Ung;Lee, Seung-Yong;Song, Jae-Jin;Chung, Sung-Kyun;Kim, Kee-Nam;Back, Seong-Jin
    • Proceedings of the Korean Society of Applied Pharmacology
    • /
    • /
    • pp.108-108
    • /
    • 1995
  • Pharmacokinetic studies on time-course of blood levels, tissue distribution, and excretion of G009, a potential hepatoprotective agent, were performed in male rats after a single oral dose(20mg/kg) of $\^$14/C-labelled G009. The radioactivity concentrations in plasma during 0~3 hours are low, but subsequently increase to a maximum at 12 hours after dosing. $\^$14/C-G009 was well distributed to all tissue. Tissue concentration profiles of radioactivity vary among tissues on time-course after administration. G009(single oral dosage) was distributed and/or absorbed at gastric intestines and excretional organs for initial time of 0-7 hours, and distributed to most tissue at 12-24 hours. In special, the concentration of radioactivity in tiller at 48 hours were 1% of total radioactivity of $\^$14/C-G009 administered. The expired air, urinary and fecal excretion of radioactivity within 24hours after administration were 61.5%, 1.9% and 21.2% of total radioactivity of $\^$14/C-G009 administered. The biliary excretion of radioactivity in rat increased slightly for 0-6 hours after administration. The biliary excretion of radioactivity within 48hours were 1.97%.

  • PDF

Effect of Mineral Silicates on Preparation of Spray Dried Agglomerates with CMEC (분무건조법으로 제조한 Carboxy Methyl Ethyl Cellulose 피복입자에 대한 Mineral Silicates의 영향)

  • Min, Shin-Hong;Yang, Joong-Ik;Kwon, Jong-Won;Yu, Bong-Gyu
    • Journal of Pharmaceutical Investigation
    • /
    • v.14 no.4
    • /
    • pp.170-177
    • /
    • 1984
  • For the purpose of improving the fluidity of enteric-coated powders, various mineral silicates were added during spray drying process. Aqueous slurries of cimetidine, mineral silicates containing CMEC (carboxy methyl ethyl cellulose) were spray dried using a centrifugal wheel atomizer. The finely agglomerated powders obtained by this process were flowing as opposed to the original powders. The effect of four mineral silicates (colloidal silica, talc, bentonite, and kaolin) on the micromeritic properties and dissolution profiles of spray dried agglomerates were examined.

  • PDF

General Pharmacology of G009, a Polysaccharide Isolated from Ganoderma lucidum IY 009

  • Kim, Su-Ung;Lee, Seung-Yong;Lee, Seung-Mok;Jeong, Hoon;Hyun, Ik-Sang;Lee, June-Woo;Han, Man-Deuk;Lee, Eun-Bang;Cheon, Seon-Ah;Kim, Sang-Mee;Kim, Kyung-Ran
    • Proceedings of the Korean Society of Applied Pharmacology
    • /
    • /
    • pp.106-106
    • /
    • 1995
  • A polysaccharide, G009, isolated from Ganoderma lucidum IY009 subjected to investigating on general pharmacology. This material at the large oral doses of 1000 and 2000mg/kg in mice did neither exhibit any abnormal behaviors nor effects on central nervous system. It also had no influences on hexobarbital-induced sleeping time, rotarod test and spontaneous activity test at each oral dose of 1000mg/kg in mice. No effects on the body temperature and on acetic acid induced writhing syndrome in mice were observed with its oral administration at 1000mg/kg, and the convulsions induced by strychnine and pentetrazole were not inhibited at its oral doses of 1000mg/kg in mice. The solution of G009 as given intravenously at the doses of 30 and 60mg/kg in rabbit had no influences on blood pressure and respiration rates and depth. In isolated organs of rat uterus and fundus muscles and guinea-pig ileum and trachea, it did not show any contraction or relaxation at the concentration of 2$\times$10$^{-3}$g/ml, and the contractive actions produced by oxytocin, acetylcholine, serotonin and histamine did not inhibited by the same doses. This material showed no effect on intestinal propulsion test in mice and gastric secretion in rats at the oral doses of 1000mg/kg. However, it is interesting that the material exhibited potent inhibition of acidified aspirin induced gastric damage at the doses of 500 and 1000mg/kg in rats.

  • PDF

Pharmacokinetics of a New Antigastritic Agent, Eupatilin, an Active Component of StillenE®, in Rats

  • Jang, Ji-Myun;Park, Kyung-Jin;Kim, Dong-Goo;Shim, Hyun-Joo;Ahn, Byung-Ok;Kim, Soon-Hoe;Kim, Won-Bae
    • Biomolecules & Therapeutics
    • /
    • v.11 no.3
    • /
    • pp.163-168
    • /
    • 2003
  • Pharmacokinetics of eupatilin (an active components of $Stillen^{\circledR}$, a new antigastritic agent) were investigated after both intravenous and oral administration at a dose of 30mg/kg to rats. After intravenous administration, the plasma concentrations of unchanged eupatilin declined rapidly with a mean terminal half-life of 0.101 h. Eupatilin was eliminated fast in rats; the total body clearance was 121 mL/min/kg. Eupatilin was mainly metabolized in rats; the percentage of intravenous dose of eupatilin excreted in 24 h urine and feces as unchanged eupatilin was only 2.5 and 0.919%, respectively. Eupatilin was mainly metabolized to form its glucuronide conjugate; after intravenous administration, 15.9 and 51.7% of intravenous dose was excreted in 24 h urine and feces, respectively, as eupatilin plus its glucuronide. After oral administration, the absolute bioavailability was only 3.86% based on $AUC_{0-24h}$ of eupatilin plus its glucuronide. Approximately 68.5% of oral dose was not absorbed from the entire gastrointestinal tract. Therefore, it could be concluded that the superior effect of eupatilin in experimental animal models of gastric ulcer and inflammatory bowel disease after oral administration could be due to the local action of eupatilin. Further pharmacokinetic studies to elucidate the local action of eupatilin are required.

Interaction of Erythrosine with Several Pharmaceutical Gelatins (Erythrosine과 수종(數種) 젤라틴간의 상호작용(相互作用))

  • Min, Shin-Hong;Kwon, Jong-Won;Jheong, Yeoub
    • Journal of Pharmaceutical Investigation
    • /
    • v.14 no.4
    • /
    • pp.183-188
    • /
    • 1984
  • The interactions of FD & C Red No.3 (erythrosine) in 1 or 2% concentrations with various types of pharmaceutical gelatins were studied. In visible region spectroscopy type A gelatin showed 6 nm bathochromic shift in ${\lambda}_{max}$ of erythrosine, but no shifts were observed in other gelatins. Various results were obtained in the decrease of absorbance from 0.06 to 0.25. In dissolution study, the gelatin that showed the greatest spectral change exhibited the worst profile. From above results, it is concluded that erythrosine interacted to the greatest extent with type A gelatin and in the case of type B gelatin the degree of the interaction in different according to their specifications.

  • PDF

Drug Safety Evaluation in the United States of America

  • Yoon, Young-H.;Johnson, Charles A.;Soltys, Randolph A.;Sibley, Peter L.
    • Korean Journal of Veterinary Pathology
    • /
    • v.1 no.2
    • /
    • pp.91-96
    • /
    • 1997
  • General steps in the discovery and development of novel drugs in the United States are presented. The first step is the discovery of novel drugs. Brief histories and mechanisms of a few novel drugs in the American market are outlined. In this presentation preclinical animal toxicologic studies (drug safety evaluateion) are emphasized in regard to drug development. When preclinical animal studies have defined the toxicity and the doses at which it occurs an Investigational new Drug Application (IND) is submitted to the Food and Drug Administration (FDA) An IND notifies the FDA the intention to begin testing a novel drug in human subjects.

  • PDF

Newly Established Drug Delivery Systems Company Database (새로운 약물전달체계 회사 데이터베이스의 구축)

  • Han, In-Gu;Chung, Hes-Son
    • Journal of Pharmaceutical Investigation
    • /
    • v.38 no.6
    • /
    • pp.429-432
    • /
    • 2008
  • Drug delivery systems (DDS) have entered mainstream in the pharmaceutical industry in the recent years. Major pharmaceutical companies as well as small or medium-sized biotechnology companies are developing various DDS-based products. We have established Drug Delivery System Company Database, which is an online searchable database of companies that develop DDS-based products and technologies or supply formulations and/or materials. Company summary, products and key technologies are listed in the database. DDS technology fields also include administration routes and indications of drugs. DDS terminologies, Statistical analysis, Useful Links, Glossary and Comments pages are also provided.